Clinical trials
Alzheimer's Disease Diagnosis clinical trials
Below are recruiting alzheimer's disease diagnosis clinical trials, each written for real people, not researchers. We’re tracking 305 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06582199Recruiting
Personalized Alzheimer's study using brain scans and spinal fluid
This study looks at how to better predict and understand Alzheimer's disease by using advanced brain scans and spinal fluid tests. It aims to find ways to identify people who stay healthy longer despite risk factors.
ParisAges 50–90 - NCT07651319RecruitingPhase 1/Phase 2
IL-2 and Semaglutide Treatment for Alzheimer's Disease
This study tests whether two drugs—IL-2 (an immune-boosting medication) and semaglutide (a diabetes drug that may help brain function)—can slow memory loss in people with Alzheimer's disease. Researchers believe these drugs together might help reduce brain inflammation and protect memory.
Houston, TexasAges 50–86 - NCT07618481Recruiting
Brain Stimulation Study for Alzheimer's Disease
This study tests whether a special type of brain stimulation called 40Hz BCI (brain-computer interface) might help slow memory loss in people with Alzheimer's disease. You would receive daily stimulation sessions at home with help from a caregiver.
Shanghai, Shanghai MunicipalityAges 50–80 - NCT05395624RecruitingPhase 1/Phase 2
Safety imaging study of a PET tracer in ALS, Alzheimer, MS, Parkinson
This early-phase study tests the safety of a radioactive tracer (“18F-OP-801”) and how the tracer moves through the body (biodistribution) in people with ALS, Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and in healthy volunteers. It also measures how the body processes the tracer (“pharmacokinetics”) to support future studies.
San Francisco, CaliforniaAges 18–80 - NCT07866768Recruiting
Ultrasound treatment to clear brain waste in early memory loss
This study tests a low-intensity ultrasound treatment aimed at helping the brain clear out harmful protein buildup linked to Alzheimer's disease. It is for people 65 and older with mild cognitive impairment (slight but noticeable memory problems) and a positive test for amyloid, a protein in the brain.
San Francisco, CaliforniaAges 65 years+ - NCT07213700Recruiting
Alzheimer's disease long-term study
This study follows people with Alzheimer's disease over time to learn more about the condition and improve future care. It is an observational study, meaning participants receive their usual care while researchers collect information.
MelbourneAges 18 years+ - NCT07239843Enrolling by invitation
Study of blood markers and mental health in brain diseases
This study looks at how social factors and blood markers relate to psychiatric symptoms in people with brain diseases or mental disorders. It aims to find new ways to understand and diagnose these conditions.
Barcelona, BarcelonaAges 18 years+ - NCT07731191Recruiting
Digital tools to predict Alzheimer's risk factors
This study uses smartphone tools to track early signs of Alzheimer's by analyzing risk factors. It is for people with mild cognitive issues (MCI) or subjective cognitive decline (SCD) who do not have dementia.
Brescia, BSAges 18 years+ - NCT07380204Recruiting
Measuring Hsp90 in the brain with a PET scan
This study uses a special PET scan to measure a protein called Hsp90 in the brain. It aims to understand how Hsp90 levels differ in healthy people and those with Parkinson's, Alzheimer's, or ALS, which may lead to new treatments.
Leuven, Vlaam-BrabantAges 18–70 - NCT05919485Recruiting
Brain stimulation study for mild cognitive problems in Parkinson’s
This trial tests whether a type of noninvasive brain stimulation (tDCS) can improve thinking and memory in people with mild cognitive impairment in Parkinson’s disease. You may be eligible if you have these diagnoses, are on stable medications, and can safely complete brain scan/testing.
Antalya, AlanyaAges 45–80 - NCT05336695RecruitingPhase 1/Phase 2
Brain scan study to measure fibrin in Alzheimer’s
This early study (Phase 1/2) uses brain imaging to look for “fibrin” (a blood-clot–related protein) in people with Alzheimer’s disease and related conditions. The goal is to understand whether fibrin changes can be seen on scans and what it might mean for Alzheimer’s.
Boston, MassachusettsAges 55–90 - NCT06023407Enrolling by invitation
Heat therapy for blood sugar and Alzheimer's prevention
This study tests whether regular heat therapy (like sitting in a hot tub) can help improve blood sugar control and lower the risk of Alzheimer's disease in older women who have metabolic problems.
Kansas City, KansasAges 65 years+ - NCT05741853Recruiting
Speech therapy study for bilingual people with primary progressive aphasia
This study looks at how well speech-language therapy works in bilingual people with primary progressive aphasia, a condition that gradually affects language. It also tests whether different language skills (Spanish/Catalan or Spanish/English) affect response to treatment.
Austin, TexasAges 40 years+ - NCT06596746Recruiting
Tracking markers for neurodegenerative diseases
This study tracks changes in people with Parkinson's disease, other movement disorders, or cognitive decline to find better ways to measure disease progression.
Cassino, FrosinoneAges 10 years+ - NCT04701177Enrolling by invitation
Smartphone-based study of brain biomarkers in memory clinic patients
This observational study follows people with (or at risk for) Alzheimer’s-related brain changes and a comparison group without them. It uses clinic visits, cognitive testing, questionnaires, and possibly a spinal fluid test to better understand brain biomarkers and how they relate to thinking and daily life.
Corfu, CorfuAges 45 years+ - NCT03217396Recruiting
Study blood and MRI markers in people with multiple sclerosis
This study looks for signs of “synapse damage” in multiple sclerosis using blood tests and brain imaging (MRI). The goal is to find biomarkers that may help better understand MS and how it changes over time.
Pozzilli, IserniaAges 18–65 - NCT07688460RecruitingPhase 4
Blood test to monitor Alzheimer's drug Lecanemab
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
Yiwu, ZhejiangAges 50–90 - NCT07516119Recruiting
Predicting Alzheimer's Risk Before Memory Loss Occurs
This study identifies people at high risk for Alzheimer's disease before symptoms develop, using genetics and digital tools to track brain health over time. If you qualify, you'll help researchers understand who will develop cognitive decline and potentially enable earlier interventions.
San Diego, CaliforniaAges 55 years+ - NCT07236190RecruitingPhase 2
Testing NPC-1 for people with Alzheimer's signs
This study tests whether a medicine called NPC-1 can help people with mild memory or thinking problems or early-stage Alzheimer's. It looks at a blood marker to see if the treatment may slow down the disease.
Boston, MassachusettsAges 55 years+ - NCT05187819Recruiting
Blood test to help diagnose possible Alzheimer’s
This trial checks whether a simple blood test can help doctors diagnose Alzheimer’s in people who seem to have memory problems. If you’re being evaluated for possible dementia, your doctor may refer you to a memory clinic for testing and follow-up.
StavangerAges 40–100 - NCT06567431Recruiting
Blood and tears in alzheimer's disease
This study looks at different fluids from the body, like blood and tears, to find better ways to diagnose and track alzheimer's and related dementias. It compares people with these conditions to healthy volunteers to see what biological markers differ.
CopenhagenAges 30 years+ - NCT06528964Recruiting
Skin protein study for Alzheimer's, Parkinson's, and related disorders
This study looks at the skin of people with memory or movement disorders (like Alzheimer's, Parkinson's, ALS) to find proteins that may help diagnose these conditions. If you have one of these diseases or are a healthy older adult, you may be able to join by giving a small skin sample.
San Luis Potosí CityAges 45 years+ - NCT07531732Recruiting
Self-Awareness and Social Thinking in Brain Diseases
This study explores how awareness of oneself and the ability to understand others' thoughts relates to two types of brain diseases: frontotemporal dementia (a disease affecting personality and behavior) and Alzheimer's disease. The research may help doctors better understand these conditions and improve care.
ParisAges 50–80 - NCT06570109Enrolling by invitation
Risk and outcomes of frailty in Alzheimer's dementia
This study looks at how frailty affects people newly diagnosed with Alzheimer's dementia. It aims to understand risk factors and outcomes to help improve care.
AalborgAges 65 years+
Hear when a new Alzheimer's Disease Diagnosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer's disease diagnosis?
- Yes. Clin2 currently lists 305 recruiting alzheimer's disease diagnosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer's disease diagnosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer's disease diagnosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.